# Bausch + Lomb to acquire Xiidra and other ophthalmology assets from Novartis for $1.75B

Bausch + Lomb Ireland Limited, a subsidiary of Bausch + Lomb Corporation, has agreed to acquire Xiidra and other ophthalmology assets from Novartis for $1.75 billion in cash at closing, plus up to $750 million in milestone payments. The transaction is expected to close by end of 2023.

- Type: Acquisition
- Announced: 2023-06-30
- Where: United States
- Value: $1.75B
- Status: announced
- Products: Xiidra, ophthalmology assets
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Bausch + Lomb](https://endata.com/companies/8199.md) (acquirer)
- [Novartis Pharma AG](https://endata.com/companies/71314.md) (target)
- [Novartis Finance Corporation](https://endata.com/companies/71315.md) (target)

## Sources

- [secwatch.observer](https://secwatch.observer/filing/0001193125-23-183284), 2023-07-07: "On June 30, 2023, a wholly owned subsidiary of Bausch + Lomb Corporation entered into a Stock and Asset Purchase Agreement with Novartis Pharma AG, Novartis Finance Corporation."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.